GeNeuro: Availability of Documents and Information for the Annual Shareholders’ Meeting of May 31, 2022
GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a
biopharmaceutical company developing treatments for
neurodegenerative and autoimmune diseases, such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe
neuropsychiatric consequences of COVID-19 (post-COVID), informs its
shareholders that the 2022 Annual General Meeting will be held on
Tuesday May 31, 2022 at 9.30am at its head office, 3, chemin du
Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.
Based on article 27 of Ordinance 3 on Measures to combat the
Coronavirus of 19 June 2020 (COVID-19 Ordinance 3, status as of May
2, 2022), the Board of Directors has decided that shareholders of
the Company may exercise their rights at this Ordinary General
Meeting exclusively through the Independent Proxy. The conduct of
the Ordinary General Meeting remains subject to additional measures
that may be issued by the Swiss authorities.
The notice for the meeting, including the agenda of the day as
well as the motions put to the vote, has been published today in
the Feuille Officielle Suisse du Commerce.
The documents and preliminary information concerning this
meeting are being made available to the shareholders and can be
consulted on the website of the Company: www.geneuro.com, under the section Investors /
Documentation / Shareholders meeting.
It is also possible to consult the documents at the Company’s
headquarters, chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates. Each
shareholder has the right to request a hard copy of those
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It has rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
version on businesswire.com: https://www.businesswire.com/news/home/20220510006008/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
48 00 firstname.lastname@example.org
NewCap (France) Louis-Victor Delouvrier / Mathilde Bohin
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 00
Historical Stock Chart
Von Okt 2022 bis Nov 2022
Historical Stock Chart
Von Nov 2021 bis Nov 2022